tbuckley/cabot-search huggingface dataset:
Hypertension and Cyclosporine
Authors: Jacques J. Sennesael, Alain G. Dupont, Dierik L. Verbeelen, L. Van Haelst, Leendert C. Paul
Journal: Annals of Internal Medicine (1986)

Letters and Corrections1 May 1986Hypertension and CyclosporineJACQUES J. SENNESAEL, M.D., ALAIN G. DUPONT, M.D., DIERIK L. VERBEELEN, M.D., L. VAN HAELST, M.D., Ph.D., LEENDERT C. PAUL, M.D., Ph.D.JACQUES J. SENNESAEL, M.D.Search for more papers by this author, ALAIN G. DUPONT, M.D.Search for more papers by this author, DIERIK L. VERBEELEN, M.D.Search for more papers by this author, L. VAN HAELST, M.D., Ph.D.Search for more papers by this author, LEENDERT C. PAUL, M.D., Ph.D.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-104-5-729_1 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptTo the editor: Mild and reversible elevation of blood pressure is a common manifestation of cyclosporine toxicity in organ graft recipients (1) and patients with ocular inflammatory diseases of autoimmune origin (2). We noted severe and irreversible hypertension in a patient receiving this drug for treatment of Graves' ophthalmopathy.A 39-year-old white woman with Graves' disease had severe hyperthyroidism and eye symptoms. Her blood pressure was 160/85 mm Hg on admission. Treatment was begun with methimazole, 50 mg/d; plasma exchange; and cyclosporine, 10 mg/kg body weight d. The dosage of cyclosporine was tapered over 1 month to a maintenance dosage...References1. BENNETTPULLIAM WJ. Cyclosporine nephrotoxicity. Ann Intern Med. 1983;99:851-4. LinkGoogle Scholar2. PALESTINENUSSENBLATTCHAN ARC. Side effects of systemic cyclosporine in patients not undergoing transplantation. Am J Med. 1984;77:652-6. CrossrefMedlineGoogle Scholar3. DRATMAN M. Thyroid function and high blood pressure. Cardiovasc Med. 1976;1:319-31. Google Scholar4. BERGSTRANDBOHMANFARNSWORTH ASW. Renal histopathology in kidney transplant recipients immunosuppressed with cyclosporin A: results of an international workshop. Clin Nephrol. 1985;24:107-19. MedlineGoogle Scholar5. MURRAYPALLERFERRIS BMT. Effect of cyclosporine administration on renal hemodynamics in conscious rats. Kidney Int. 1985;28:767-74. CrossrefMedlineGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: University of Leiden Leiden the Netherlands PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited BySystemic Hypertension Associated with Cyclosporine: A Review 1 May 1986Volume 104, Issue 5Page: 729-729KeywordsAutoimmune diseasesBlood plasmaBlood pressureBody weightDrugsEye diseasesHypertensionHyperthyroidismToxicity Issue Published: 1 May 1986 PDF DownloadLoading ...
Heterozygous β-thalassemia with thalassemia intermedia phenotype
Authors: D. Gasperini, L. Perseu, M.A. Melis, L. Maccioni, M.C. Sollaino, E. Paglietti, A. Cao, R. Galanello
Journal: American Journal of Hematology (1998)

In this study we investigated the molecular bases of the β-thalassemia intermedia phenotype in six patients belonging to two unrelated families of Sardinian descent. Sequence analysis of the β globin gene from these patients detected, as the sole abnormality, the heterozygosity for the codon 39 nonsense mutation. The Aγ and Gγ promoters as well as the HS2 and HS3 core sequences of the β globin LCR from these patients, did not show any non-polymorphic nucleotide variation from the consensus sequence. One of the parents was heterozygous for codon 39 nonsense mutation but showed the β-thalassemia carrier phenotype; the other was hematologically normal and had an entirely normal β globin gene sequence. In both families, other members showed the typical hematological phenotype, clinically silent, of heterozygous β thalassemia. To explain the thalassemia intermedia phenotype, we postulated the presence of an unknown molecular defect interacting with the β globin gene mutation. Haplotype analysis excluded that this postulated defect lies in the β globin gene cluster. Am. J. Hematol. 57:43–47, 1998. © 1998 Wiley-Liss, Inc.
Controlled Extracellular Matrix Degradation in Breast Cancer Tumors Improves Therapy by Trastuzumab
Authors: Ines Beyer, Zongyi Li, Jonas Persson, Ying Liu, Ruan van Rensburg, Roma Yumul, Xiao-Bing Zhang, Mien-Chie Hung, André Lieber
Journal: Molecular Therapy (2010)

Extracellular matrix (ECM) in solid tumors affects the effectiveness of therapeutics through blocking of intratumoral diffusion and/or physical masking of target receptors on malignant cells. In immunohistochemical studies of tumor sections from breast cancer patients and xenografts, we observed colocalization of ECM proteins and Her2/neu, a tumor-associated antigen that is the target for the widely used monoclonal antibody trastuzumab (Herceptin). We tested whether intratumoral expression of the peptide hormone relaxin (Rlx) would result in ECM degradation and the improvement of trastuzumab therapy. As viral gene delivery into epithelial tumors with extensive tumor ECM is inefficient, we used a hematopoietic stem cell (HSC)-based approach to deliver the Rlx gene to the tumor. In mouse models with syngeneic breast cancer tumors, HSC-mediated intratumoral Rlx expression resulted in a decrease of ECM proteins and enabled control of tumor growth. Moreover, in a model with Her2/neu-positive BT474-M1 tumors and more treatment-refractory tumors derived from HCC1954 cells, we observed a significant delay of tumor growth when trastuzumab therapy was combined with Rlx expression. Our results have implications for antibody therapy of cancer as well as for other anticancer treatment approaches that are based on T-cells or encapsulated chemotherapy drugs. Extracellular matrix (ECM) in solid tumors affects the effectiveness of therapeutics through blocking of intratumoral diffusion and/or physical masking of target receptors on malignant cells. In immunohistochemical studies of tumor sections from breast cancer patients and xenografts, we observed colocalization of ECM proteins and Her2/neu, a tumor-associated antigen that is the target for the widely used monoclonal antibody trastuzumab (Herceptin). We tested whether intratumoral expression of the peptide hormone relaxin (Rlx) would result in ECM degradation and the improvement of trastuzumab therapy. As viral gene delivery into epithelial tumors with extensive tumor ECM is inefficient, we used a hematopoietic stem cell (HSC)-based approach to deliver the Rlx gene to the tumor. In mouse models with syngeneic breast cancer tumors, HSC-mediated intratumoral Rlx expression resulted in a decrease of ECM proteins and enabled control of tumor growth. Moreover, in a model with Her2/neu-positive BT474-M1 tumors and more treatment-refractory tumors derived from HCC1954 cells, we observed a significant delay of tumor growth when trastuzumab therapy was combined with Rlx expression. Our results have implications for antibody therapy of cancer as well as for other anticancer treatment approaches that are based on T-cells or encapsulated chemotherapy drugs.
Insulin has never become a cheap generic drug in the US because of companies' small changes to "evergreen" the patent
Authors: S. Mayor
Journal: BMJ (2015)

Drug companies have made incremental improvements to insulin that have kept it as a patented medicine in the United States for more than 90 years, shows a study tracing the drug’s history.

“The history of insulin highlights the limits of generic competition as a public health framework,” said the study authors, Jeremy Greene and Kevin Riggs, of Johns Hopkins University School of Medicine in Baltimore, USA, writing in the New England Journal of Medicine .[1] They warned, “Nearly a century after its discovery, there is still …
When I use a word...: Fingerprints
Authors: J. Aronson
Journal: BMJ (1997)

Fond though doctors are of using long words of Greek and Latin origins, in some cases we use ordinary English words. We say hiccup (not singultus), yawn (not pandiculation), and fingerprints (not dermatoglyphics).

The recent discovery that koala bears have fingerprints that more closely resemble those of humans than chimpanzees' fingerprints do is said to support the hypothesis that fingerprints evolved as an aid to climbing. Whether or not that is so, fingerprints have been …
P11.03 * OPTIC NERVE INFILTRATION OF PRIMARY CNS LYMPHOMA
Authors: G. Ahle, K. Hoang-Xuan, N. Cassoux, V. Touitou, C. Soussain, C. Humbrecht-Kraut, I. Manoila, M. Bouyon, R. Schroers, C. Houillier
Journal: Neuro-Oncology (2014)

BACKGROUND: Visual impairment in Primary CNS lymphoma (PCNSL) in most of the cases is due to an intraocular lymphomatous involvement, especially uveitis. Optic nerve infiltration (ONI) in PCNSL is a rare condition. We sought to describe its clinical presentation, imaging characteristics, and outcomes. METHODS: Patients with ONI of PCNSL were retrospectively identified from 1998 to 2014 from the databases of the university hospitals Pitié-Salpêtrière (Paris) and René Huguenin (Saint-Cloud), and the academic teaching hospital Pasteur (Colmar), France. Exclusion criteria were intraocular involvement, orbital lymphoma, or other systemic lymphoma. Clinical presentation, neuroimaging, biological features, treatment and outcomes were assessed from their medical records. RESULTS: Only 6 of 710 PCNSL were identified as presenting ONI. Patients' median age at presentation was 65 years (49-78), 5 were women. 2 patients had ONI at initial diagnosis, 3 at 1st relapse after HD-MTX based chemotherapy, and 1 at 2nd relapse after HD-MTX, salvage chemotherapy and high-dose chemotherapy with autologous stem cell transplant. Clinical presentation: Rapidly progressive visual impairment without red eyes (6/6 patients), painless (4/6), unilateral (4/6), bilateral (2/6), bilateral hemianopia (2/6). MRI: Optic nerve swelling (3/6), contrast-enhancement of the entire ON (5/6) or of the ON sheath (1/6); Localization of ONI: Chiasmic (3/6), cisternal (3/6), intracanalicular (3/6), and intraorbital (4/6). Additional CNS lesions were seen in 4/6. Systemic lymphoma was excluded in all patients; lumbar puncture was done in 4/6 proving leptomeningeal disease in 2. Median delay from symptom onset to treatment: 25 days (10-140). Treatment: Different chemotherapy regimens were administered but lymphoma recurred in the majority. Clinical outcome: Partial recovery (2/6 patients), persisting low vision or blindness (4/6). Radiological outcome: Complete remission (4/6), partial remission (1/6), stable disease (1/6). Median PFS after ONI: 11 months (3-11), OS: 32 months (12-40). CONCLUSIONS: Intraocular involvement is observed in about 15% of PCNSL, clinically marked by slowly progressive visual deterioration over several months, usually caused by posterior uveitis. Lymphomatous infiltration of the optic nerve is characterized by a rapidly progressive severe visual impairment. In patients with ONI as initial presentation of PCNSL, it is difficult to establish the diagnoses as differential diagnosis are broad. In these patients, optic nerve biopsy should be discussed only in absence of cerebral lesions. At relapse, clinical presentation, neuroimaging and the absence of intraocular involvement may help to establish the diagnosis. As optic nerve functional outcome is poor, rapid treatment might improve clinical outcome. ACKNOWLEDGEMENTS: LOC national network (INCa)
Bone SPECT/CT Detection of a Sequestrum in Chronic-Infected Nonunion of the Tibia
Authors: Jan L. Madsen
Journal: Clinical Nuclear Medicine (2008)

Sequestra are dead pieces of bone most often seen in long bones affected with prior or current infection. In addition to antibiotic therapy, chronic osteomyelitis with sequestration requires surgical debridement for cure. The author presents a case of tibial fracture associated with chronic osteomyelitis, nonunion, and the presence of a sequestrum that was detected by bone SPECT/CT.
A Rapid Screening Method for Wound Dressing by Cell‐on‐a‐Chip Device
Authors: Qilong Zhao, Shiwen Wang, Yunyan Xie, Wenfu Zheng, Zhuo Wang, Le Xiao, Wei Zhang, Xingyu Jiang
Journal: Advanced Healthcare Materials (2012)

Abstract This report demonstrates an in vitro method for screening wound dressing candidates that can minimize the use of animals for developing better methods for wound care. The development of materials and formulations for wound dressings, an important application of biomaterials, is laboriously and ethically challenging because of the use of a large number of animals. A method for rapid and effective screening of wound dressings in vitro , therefore, is in great need. A cell‐on‐a‐chip model was used to simulate the cutaneous wound in vitro and screen the performances of several electrospun fibrous wound dressings in enhancing wound healing. For comparison, the performances of wound dressings were also evaluated in a rat model. It was found that the results acquired by microchip model corroborates well with animal experiments. It is the first time, as far as we know, that a good correlation between in vitro and in vivo results is reported for fibrous wound dressings. The cell‐on‐a‐chip wound model we developed here may change the way that scientists screen candidates for wound dressings.
Indomethacin—Its Rightful Place in Treatment
Authors: CHARLEY J. SMYTH
Journal: Annals of Internal Medicine (1970)

Indomethacin has been in clinical use for 7 years and has aroused more interest, controversy, and discussion than any other antirheumatic agent since the corticoids. Good to excellent results have been obtained in a high percentage of patients with ankylosing spondylitis and acute gouty arthritis, and it has been shown to have analgesic value in degenerative joint disease, especially of the hips. There is widely diverse opinion regarding its therapeutic effect in rheumatoid arthritis. Clinical benefits have also been reported in many other connective tissue diseases including psoriatic arthritis, Reiter's syndrome, fibrositis, periarthritis of the shoulder, polymyositis, and lupus pericarditis.
Effects of Metformin With or Without Supplementation With Folate on Homocysteine Levels and Vascular Endothelium of Women With Polycystic Ovary Syndrome
Authors: Stefano Palomba, Angela Falbo, Francesco Giallauria, Tiziana Russo, Achille Tolino, Fulvio Zullo, Annamaria Colao, Francesco Orio
Journal: Diabetes Care (2009)

To evaluate whether the administration of metformin exerts any effects on serum homocysteine (Hcy) levels in patients with polycystic ovary syndrome (PCOS) and whether supplementation with folate enhances the positive effects of metformin on the structure and function of the vascular endothelium.A total of 50 patients affected by PCOS, without additional metabolic or cardiovascular diseases, were enrolled in a prospective nonrandomized placebo-controlled double-blind clinical study. They were grouped into two treatment arms that were matched for age and BMI. Patients were treated with a 6-month course of metformin (1,700 mg daily) plus folic acid (400 microg daily; experimental group, n = 25) or placebo (control group, n = 25). Complete hormonal and metabolic patterns, serum Hcy, folate, vitamin B12, endothelin-1 levels, brachial artery diameter at the baseline (BAD-B) and after reactive hyperemia (BAD-RH), flow-mediated dilation, and intima-media thickness in both common carotid arteries were evaluated.After treatment, a significant increase in serum Hcy levels was observed in the control group compared with the baseline values and the experimental group. A beneficial effect was observed in the concentrations of BAD-B, BAD-RH, flow-mediated dilation, intima-media thickness, and serum endothelin-1 in both groups. However, the results were improved more significantly in the experimental group than in the control subjects.Metformin exerts a slight but significant deleterious effect on serum Hcy levels in patients with PCOS, and supplementation with folate is useful to increase the beneficial effect of metformin on the vascular endothelium.
PREDICTORS OF EARLY COMPLICATIONS AND MORTALITY AFTER DE NOVO IMPLANTABLE CARDIOVERTER-DEFIBRILLATOR IMPLANTATION, UPGRADE OR GENERATOR REPLACEMENT
Authors: Christopher Kolibash, Rachel Pedersen, Linda Francaviglia, Renee Koeberl, Jasbir Sra, Vikram Nangia
Journal: Journal of the American College of Cardiology (2013)
Cost effectiveness of day and inpatient psychiatric treatment: results of a randomised controlled trial
Authors: F. Creed, P. Mbaya, S. Lancashire, B. Tomenson, B. Williams, S. Holme
Journal: BMJ (1997)

<h3>Abstract</h3> <b>Objective:</b> To compare direct and indirect costs of day and inpatient treatment of acute psychiatric illness. <b>Design:</b> Randomised controlled trial with outcome and costs assessed over 12 months after the date of admission. <b>Setting:</b> Teaching hospital in an inner city area. <b>Subjects:</b> 179 patients with acute psychiatric illness referred for admission who were suitable for random allocation to day hospital or inpatient treatment. 77 (43%) patients had schizophrenia. <b>Interventions:</b> Routine inpatient or day hospital treatment. <b>Main outcome measures:</b> Direct and indirect costs over 12 months; clinical symptoms, social functioning, and burden on relatives over the follow up period. <b>Results:</b> Clinical and social outcomes were similar at 12 months, except that inpatients improved significantly faster than day patients and burden on relatives was significantly less in the day hospital group at one year. Median direct costs to the hospital were £1923 (95% confidence interval £750 to £3174) per patient less for day hospital treatment than inpatient treatment. Indirect costs were greater for day patients; when these were included, overall day hospital treatment was £2165 cheaper than inpatient treatment (95% confidence interval of median difference £737 to £3593). Including costs to informants when appropriate meant that day hospital treatment was £1994 per patient cheaper (95% confidence interval £600 to £3543). <b>Conclusions:</b> Day patient treatment is cheaper for the 30-40% of potential admissions that can be treated in this way. Carers of day hospital patients may bear additional costs. Carers of all patients with acute psychiatric illness are often themselves severely distressed at the time of admission, but day hospital treatment leads to less burden on carers in the long term. <h3>Key messages</h3> When inpatient treatment is avoidable day hospital treatment is cheaper for acutely ill psychiatric patients Carers of acutely ill psychiatric patients experience severe distress and warrant help in their own right Inpatient treatment relieves symptoms more rapidly than day hospital treatment but may lead to increased burden on carers one year later
Galen: On the Usefulness of the Parts of the Body
Authors: Lester S. King
Journal: JAMA (1969)

<b>Galen's System of Physiology and Medicine,</b>by Rudolph E. Siegel, 419 pp, with illus, $23.50, Basel: S. Karger (White Plains, NY: Albert J. Phiebig), 1968 Galen was a prolific writer, yet the modern student can have trouble in finding texts to study. Very few scholars can consult the original Greek, and those restricted to modern languages find only a few works available in English. The almost simultaneous publication of two major Galenic studies represents an important event in medical history. Mrs. May translated into English one of Galen's most significant writings, the<i>De Usu Partium—On the Usefulness of the Parts of the Body</i>. The only other modern translation was into French, by Daremberg, published over a century ago and now relatively rare. The text is a combination of anatomy and physiology, describing the body parts and their function, with special reference to the purposes and goals for which these were
Effect of one gold salt, of betamethasone, and of aspirin on the chemotaxis of human neutrophils measured in vitro.
Authors: A Pecoud, A Leimgruber, P C Frei
Journal: Annals of the Rheumatic Diseases (1980)

The effects of 1 gold salt, of betamethasone, and of acetylsalicylate on the chemotaxis of human neutrophils were compared in normal volunteers by means of a modified Boyden chamber. The gold salt inhibited chemotaxis by reducing both cell migration capacity and the capacity of plasma to attract the cell. Betamethasone reduced cell migration capacity, but not the chemoattractant capacity of plasma. Acetylsalicylate had no effect on these functions.
Reticulate hyperpigmentation distributed in a zosteriform fashion
Authors: A. Patrizi, V. Lernia, C. Varotti
Journal: British Journal of Dermatology (1989)

Journal Article Reticulate hyperpigmentation distributed in a zosteriform fashion Get access A. Patrizi, A. Patrizi Department of Dermatology, University of Bologna, Bologna, Italy Search for other works by this author on: Oxford Academic Google Scholar V. Di Lernia, V. Di Lernia Department of Dermatology, University of Bologna, Bologna, Italy Search for other works by this author on: Oxford Academic Google Scholar C. Varotti C. Varotti Department of Dermatology, University of Bologna, Bologna, Italy Search for other works by this author on: Oxford Academic Google Scholar British Journal of Dermatology, Volume 121, Issue 2, 1 August 1989, Page 280, https://doi.org/10.1111/j.1365-2133.1989.tb01814.x Published: 01 August 1989
MELANOTIC NEOPLASMS OF THE EYE
Authors: MARY S. KNIGHT
Journal: JAMA (1924)

The origin of melanotic or pigmented neoplasms of the eye has long been a debated question. Pathologists are turning more and more to the opinion that they are epithelial in origin. If the malignant pigmented new growths elsewhere in the body are epitheliomas, why should those tumors arising in the uveal tract and having similar histologic characteristics have a different origin? It is true that, according to the old theories of pathology and embryology, it is difficult to conceive of epithelial tumors arising in the choroid; but new discoveries frequently lead to new interpretations of old facts.  Embryologically, the eye arises from an outpouching of the neural tube. This sac becomes invaginated to form the optic vesicles. Minot, 1 in introducing the subject of the development of the eye, says that the optic vesicles form the retina, the choroid coat and optic nerve of the adult eye. However, he does